Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects

Journal of the American Academy of Dermatology

Volumn 19, Issue 3, 1988, Pages 509-515

  Peterson, Larry L ^a   Woodward, William R ^a   Fletcher, William S ^a   Palmquist, Michele ^a   Tucker, Margaret A ^a   Ilias, Ajmal ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINYLDOPA;

ARTICLE; BLOOD LEVEL; DYSPLASTIC NEVUS; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL;

EID: 0023751289     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0190-9622(88)70206-6     Document Type: Article

References (15)

1. Selection of the optimum surgical treatment of stage I melanoma by depth of microinvasion: use of the combined microstage technique (Clark-Breslow)
2. Risk factors for cutaneous melanoma: a practical method of recognizing predisposed individuals
3. Origin of familial malignant melanomas from heritable melanocyt-ic lesions: the B-K mole syndrome
4. Dysplastic nevus syndrome
5. Malignant melanoma prognostic factors 7: elective lymph node dissection
6. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis
7. Plasma 5-S-cysteinyldopa correlates with tumor size in melanoma-bearing mice
8. Manual for Staging of Cancer
9. The effect of UVB light on serum concentrations of 5-S-cysteinyldopa
10. Precursors of malignant melanoma (Consensus Conference)
11. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis
12. 5-S-Cysteinyldopa in the urine of melanoma patients
13. 5-S-Cysteinyldopa in diagnosis and treatment of human malignant melanomas and ultrastructural observations
14. An estimate of the melanocyte mass in humans
15. The treatment of Stage 1 melanoma of the extremities with regional hyperthermic isolation perfusion